2/3
11:28 pm
inkt
MiNK Therapeutics Presents New Data of allo-iNKT Cell Therapy as a Potential Disease-Modifying Approach in Idiopathic Pulmonary Fibrosis at Keystone Symposia [Yahoo! Finance]
Medium
Report
MiNK Therapeutics Presents New Data of allo-iNKT Cell Therapy as a Potential Disease-Modifying Approach in Idiopathic Pulmonary Fibrosis at Keystone Symposia [Yahoo! Finance]
2/3
09:30 pm
inkt
MiNK Therapeutics Presents New Data of allo-iNKT Cell Therapy as a Potential Disease-Modifying Approach in Idiopathic Pulmonary Fibrosis at Keystone Symposia
Medium
Report
MiNK Therapeutics Presents New Data of allo-iNKT Cell Therapy as a Potential Disease-Modifying Approach in Idiopathic Pulmonary Fibrosis at Keystone Symposia
1/19
01:06 am
inkt
MiNK Therapeutics (NASDAQ:INKT) was upgraded by analysts at
Wall Street
Low
Report
MiNK Therapeutics (NASDAQ:INKT) was upgraded by analysts at
Wall Street
1/11
01:03 am
inkt
MiNK Therapeutics (NASDAQ:INKT) was downgraded by analysts at
Wall Stree
Medium
Report
MiNK Therapeutics (NASDAQ:INKT) was downgraded by analysts at
Wall Stree
1/8
12:00 pm
inkt
MiNK Therapeutics and University of Wisconsin–Madison Announce Phase 1 Clinical Trial of Allo-iNKT Cell Therapy (AgenT-797) to Evaluate Prevention of Graft-Versus-Host Disease
Low
Report
MiNK Therapeutics and University of Wisconsin–Madison Announce Phase 1 Clinical Trial of Allo-iNKT Cell Therapy (AgenT-797) to Evaluate Prevention of Graft-Versus-Host Disease
1/3
01:08 am
inkt
MiNK Therapeutics (NASDAQ:INKT) was upgraded by analysts at
Wall Street
Medium
Report
MiNK Therapeutics (NASDAQ:INKT) was upgraded by analysts at
Wall Street
12/20
01:30 am
inkt
MiNK Therapeutics (NASDAQ:INKT) was downgraded by analysts at
Wall Stree
Medium
Report
MiNK Therapeutics (NASDAQ:INKT) was downgraded by analysts at
Wall Stree
12/6
01:36 am
inkt
MiNK Therapeutics (NASDAQ:INKT) was upgraded by analysts at
Wall Street
Low
Report
MiNK Therapeutics (NASDAQ:INKT) was upgraded by analysts at
Wall Street